Home »
Academic Articles »
C »
Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma
Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma
Wei-Yu Lin
(Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Wei-Yu Lin
(School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan)
Wei-Yu Lin
(Department of Nursing, Chang Gung University of Science and Technology, Chiayi, Taiwan)
Wei-Yu Lin
(Department of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan)
Meng-Hung Lin
(Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Yao-Hsu Yang
(Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Yao-Hsu Yang
(Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Yao-Hsu Yang
(School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan)
Wen-Cheng Chen
(School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan)
Wen-Cheng Chen
(Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Cih-En Huang
(Division of Hematology Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Miao-Fen Chen
(School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan)
Miao-Fen Chen
(Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan)
Chun-Te Wu
(School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan)
Chun-Te Wu
(0Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan)
Journal: Frontiers in Surgery
•
• Frontiers Media S.A.
• ISSN: 2296-875X
Abstract
BackgroundWhether nephroureterectomy (NU) provides survival benefits in patients with stage IV upper tract urothelial carcinoma (UTUC) remains unclear. We compared the effect of chemotherapy (CT) alone with that of CT combined with NU (CT + NU) on the overall survival (OS) of patients with stage IV nonmetastatic UTUC (nmUTUC) and metastatic UTUC (mUTUC).Patients and MethodsThis multicenter retrospective cohort study included the data of patients with UTUC undergoing CT alone or CT + NU from the Chang Gung Cancer Database (2002–2015) and followed them until August 2017. OS and hazard ratios (HRs) were assessed using the Kaplan–Meier method and Cox proportional hazards model, respectively.ResultsThis study included 308 patients with stage IV UTUC, comprising 139 with nmUTUC and 169 with mUTUC. Moreover, 91 (74.6%) patients with nmUTUC and 31 (25.4%) patients with mUTUC received NU. The CT + NU group had a higher 3-year OS rate (41.0.% vs 16.7%, p < 0.001), longer median OS duration (20.7 vs 9.0 months, p < 0.001), and lower risk of death (HR, 0.48; 95% confidence interval, 0.36–0.66; p < 0.001) than did the CT-alone group. Similarly, patients with mUTUC who underwent CT + NU had a longer median OS duration (25.0 vs 7.8 months, p < 0.001) and lower risk of death (HR, 0.37; 95% confidence interval, 0.23–0.59; p < 0.001) than did those who received CT alone.ConclusionCompared with CT alone, NU + CT can provide survival benefits to patients with nonmetastatic and metastatic stage IV UTUC.
Wei-Yu Lin, Wei-Yu Lin, Wei-Yu Lin, et al. (2022). "Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma". Frontiers in Surgery. https://doi.org/10.3389/fsurg.2022.903123